Global Antinuclear Antibody Test Market - 2022-2029

Market Overview

The global antinuclear antibody test market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

The anti-nuclear antibody test (ANA) or FANA (fluorescent anti-nuclear antibody) is a blood test that detects the presence of auto-antibodies in the serum, which are antibodies produced by the body against its cells. The human immune system recognizes foreign things such as bacteria, viruses, fungus, and other microbes in normal circumstances and mounts an immune response against them. Many antibodies are produced during this immune reaction, which binds and kills any foreign particles in the body.

Market Dynamics

Technological advancements and increased R&D funding for new products are expected to drive market growth.

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) established a classification criterion for systemic lupus erythematosus (SLE) in 2019, which suggested that immunofluorescence testing on solid-phase anti-nuclear antibody screening immunoassay and HEp-2 cells with equal performance was highly preferred. Moreover, the market for anti-nuclear antibody testing is growing due to government healthcare insurance, an increase in autoimmune disorders awareness campaigns, and reimbursement regulations. For instance, The World Lupus Federation (WLF) collaborates with roughly 250 lupus organizations from 75 countries across six continents to assist lupus patients. WLF works to improve public awareness about Lupus and provide better healthcare for those who suffer from the disease. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

However, there are rigorous requirements for medical device clearance in developing economies and the demand of large resources to purchase high-priced equipment, a scarcity of competent medical personnel, and a lack of awareness of the disease and effective treatment. Thus, the market is expected to get hampered in the forecast period from the above statements.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The impact of the SARS-CoV-2 pandemic on people with arthritis has been addressed, although evidence on other rheumatic disorders, such as systemic lupus erythematosus (SLE), is rare. Thromboembolism, an imbalanced type I interferon response, and complement activation are all concerns associated with severe SARS-CoV-2 infection, just as they are with SLE. SARS-CoV-2 antibodies were evaluated and compared with SLE development and antinuclear antibody (ANA) levels in longitudinal samples taken before immunization. As a result, dependable SARS-CoV-2 antibody assays are in high demand and critical for reopening societies following lockdowns and allowing travel. Furthermore, as COVID-19 immunization programs spread worldwide, the need for reliable SARS-CoV-2 antibody assays (to confirm a successful vaccine response) will almost certainly persist in the coming years.

Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Reagents & Assay Kits segment is expected to hold the largest market share in antinuclear antibody test market

The reagents & assay kits segment is expected to dominate in 2020. The segment's growth benefits because high adoption in the clinical and scientific fields and the development of standardized procedures aid in producing reliable and repeatable outcomes. High efficiency and lower prices increase the number of reagent/assay rental agreements are some of the factors the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global antinuclear antibody test market

In 2020, North America accounted for the highest revenue share. The rising geriatric population, increasing prevalence of autoimmune diseases, growing population and healthcare spending, and an increase in the number of people covered by medical insurance in the United States are factors that the market is expected to boost in the region in the forecast period. For instance, In the United States, autoimmune illnesses are the third most prevalent cause of chronic illness. Although many autoimmune disorders are uncommon, the National Institutes of Health (NIH) estimates that they affect between 5% and 8% of the population in the United States. Autoimmune illnesses are becoming more common for unclear reasons.

Moreover, According to the American Autoimmune Related Diseases Association (AARDA), up to 50 million Americans have an autoimmune disease, costing $86 billion every year. According to the United States Department of Health and Human Services (HHS), these disorders are the fourth greatest cause of disability in women in the United States and the eighth top cause of mortality among women aged 15 to 64. Therefore, it has increased the demand for antinuclear antibody tests in the region. Thus, the North American region is expected to boost in the forecast period from the above statements.

Competitive Landscape

Major key players in the antinuclear antibody test market are Abbott Laboratories (Alere Inc), BioVision Inc, Antibodies Incorporated, PerkinElmer Inc, Zeus Scientific, Inc., Bio-Rad Laboratories, Inc., Inova Diagnostics, Thermo Fisher Scientific, Inc., Trinity Biotech plc. and Immuno Concepts.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and is based in Waltham, Massachusetts. The company offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

­Product Portfolio:

Thermo Scientific Accutex Systemic Lupus Erythematosus (SLE) Latex: It is a competitively priced qualitative and semi-quantitative serological test for the detection of antinuclear antibodies in serum or plasma as an aid in the diagnosis of systemic lupus erythematosus.

Why Purchase the Report?

Visualize the composition of the antinuclear antibody test market segmentation by product, technique, disease, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in Antinuclear antibody test market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of antinuclear antibody test market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global antinuclear antibody test market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers